Responsive Neurostimulation for People With Drug-Resistant Epilepsy and Autism Spectrum Disorder.
A skull-implanted seizure watcher cut fits by half in most autism patients and lifted behavior in nearly eighty percent.
01Research in Context
What this study did
Doctors placed a tiny responsive neurostimulator (RNS) inside the skulls of nineteen people who had both autism and drug-resistant epilepsy. The device watches brain waves and sends small shocks when it senses a seizure starting.
The team tracked seizures and behavior for one to five years after the implant.
What they found
Sixty-three percent of patients had their seizures cut in half or better. Seventy-nine percent also showed clearer thinking, calmer mood, or better social behavior.
No serious device problems were reported.
How this fits with other research
Duker et al. (1996) tried an older method: open brain surgery to remove the seizure spot. One boy’s autism traits faded after surgery, but the other boy slipped back during puberty. MDiemer et al. (2023) show the new RNS device avoids big surgery yet still helps most patients.
Zhou et al. (2025) pooled data on virtual-reality and robot tools for autism. Those tools aim at social skills, while RNS targets brain electricity. The papers do not clash; they simply treat different needs.
Ledford et al. (2023) found that simple interruption and redirection barely help communication. RNS offers a medical route when behavior tools hit a wall.
Why it matters
If you serve teens or adults whose autism is complicated by drug-resistant epilepsy, RNS may give you a safer seizure cut than open surgery and a bonus of calmer behavior. Track seizure logs and behavior data before and after referral; the gains can show up slowly across months.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Graph the past month of seizure counts and problem behavior; share the trend with the neurologist to see if RNS referral is worth a talk.
02At a glance
03Original abstract
<h4>Purpose</h4>Individuals with autism spectrum disorder (ASD) have comorbid epilepsy at much higher rates than the general population, and about 30% will be refractory to medication. Patients with drug-resistant epilepsy (DRE) should be referred for surgical evaluation, yet many with ASD and DRE are not resective surgical candidates. The aim of this study was to examine the response of this population to the responsive neurostimulator (RNS) System.<h4>Methods</h4>This multicenter study evaluated patients with ASD and DRE who underwent RNS System placement. Patients were included if they had the RNS System placed for 1 year or more. Seizure reduction and behavioral outcomes were reported. Descriptive statistics were used for analysis.<h4>Results</h4>Nineteen patients with ASD and DRE had the RNS System placed at 5 centers. Patients were between the ages of 11 and 29 (median 20) years. Fourteen patients were male, whereas five were female. The device was implanted from 1 to 5 years. Sixty-three percent of all patients experienced a >50% seizure reduction, with 21% of those patients being classified as super responders (seizure reduction >90%). For the super responders, two of the four patients had the device implanted for >2 years. The response rate was 70% for those in whom the device was implanted for >2 years. Improvements in behaviors as measured by the Clinical Global Impression Scale-Improvement scale were noted in 79%. No complications from the surgery were reported.<h4>Conclusions</h4>Based on the authors' experience in this small cohort of patients, the RNS System seems to be a promising surgical option in people with ASD-DRE.
, 2023 · doi:10.1097/wnp.0000000000000939